MedTrace Logo

Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome

NCT02302274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 209

Last updated 2019-04-18

No results posted yet for this study

Summary

The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy it proposes to apply this test to early ARVC cases in order to evaluate if ECG changes similar to those seen in Brugada Syndrome could be unmasked by flecainide iv.

Conditions

  • Brugada Syndrome
  • Arrhythmogenic Right Ventricular Cardiomyopathy

Interventions

DRUG

flecainide iv

infusion over 10 min

Sponsors & Collaborators

Principal Investigators

  • Steven Fowler, MD · NYU School of Medicine

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-01
Primary Completion
2017-07-26
Completion
2017-07-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02302274 on ClinicalTrials.gov